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1. Introduction 
An unexpectedly high prevalence of pulmonary hypertension (PH) has been detected by 
Doppler echocardiography in chronic kidney disease (CKD) patients and found to be 
associated with overall poor outcome. A number of pathogenetic mechanisms appears to act 
synergistically in producing such a condition, the relative importance of which is a matter of 
ongoing investigation. This chapter will review the literature on the topic and summarizes 
what can be drawn from published studies. Our work and experience at Sant’Andrea 
University Hospital is also extensively reported and area for future research addressed.  
2. The facts  
2.1 Pulmonary hypertension in CKD patients on maintenance hemodialysis 
Quite surprisingly, PH remained an overlooked issue in CKD patients until very recent years. 
Moving from an analysis of the backround diseases in their series of patients with PH, Yigla 
and co-workers were the first to report, in a seminal paper (Yigla et al., 2003), a PH prevalence 
as high as 39.7% in patients receiving haemodialysis (HD) through a surgically created arterio-
venous fistula (AVF). These authors found PH to be associated with cardiac output (CO) and 
anemia. They were also the first to report that temporary occlusion of the AVF by compression 
results in a reduction of both CO and systolic pulmonary artery pressure (PAPs), that PH may 
actually increase in pre-dialysis patients after renal replacement therapy (RRT) initiation, and 
that it might reduce after successful renal transplantation (Tx). This findings prompted other 
studies from the same group, focusing on the possible role of pulmonary calcifications (Yigla 
et al., 2004) and endothelin-1 (ET-1) and nitric oxide (NO) (Nakhoul et al., 2005) in the 
pathogenesis of PH in HD patients. In the first study, in a group of HD patients, 57% of whom 
with PH, no correlation was found with pulmonary calcification detected by technetium-99m 
diphosphonate scanning. In the second study they found ET-1 level to be higher in HD 
patients, both with and without PH, than in controls; no correlation with PAPs could be 
demonstrated, however. Indeed, lower NO metabolites were detected in HD patients with PH 
than in those without and in controls, as well as a blunted increase during the HD session. 
Two years later, another group reported on PH in chronic renal failure (CRF) patients 
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(Havlucu et al., 2007). Despite severe exclusion criteria, they found a echocardiographically 
estimated PAPs ≥ 35 mmHg in 14 out of 25 (56%) patients already on HD and in 9 out of 23 
(39%) patients not yet on dialysis. Patients with PH showed significantly higher CO, higher 
serum levels of parathyroid hormone (PTH), higher calcium-phosphate product and a longer 
CRF duration. They also found that the presence of an AVF was associated with a higher risk 
of PH, and that Doppler estimated AVF flow correlated with PAPs. Patients were revaluated at 
least 6 months later: quite interestingly, while patients still in pre-dialysis had deteriorated, in 
those who had started HD in the meanwhile PAPs, blood pressure (BP) and serum PTH had 
overall decreased and ejection fraction increased. In a very similar study (Abdelwhab & 
Elshinnawy, 2008), PH was detected in 20 out of 45 (44%) patients on HD and in 10 out of 31 
(32%) pre-dialysis patients on conservative treatment. Dialysis patients with PH had higher 
AVF blood flow, higher prevalence of left ventricular diastolic dysfunction and higher NT-
proBNP and TXB2 levels. A role for inflammation in the pathogenesis of PH in HD was 
addressed by researchers from Taiwan (Yu et al., 2009). In this study high sensitivity-C 
reactive protein (hs-CRP) and a number of cytokines were measured in 39 patients on long 
standing maintenance HD and correlated with the presence of PH. The prevalence of PH was 
remarkably high (61%), and patients with PH exhibited higher CO, higher AVF blood flow 
rate and, intriguingly, poorer residual renal function (RRF) and dialytic solute clearances. 
Serum levels of hs-CRP, IL-1ǃ, TNF-ǂ, IL-6 were significantly higher in patients with PH than 
in those without.  
In all these studies, echocardiography was performed within one hour from the completion of 
the HD procedure, in order to possibly avoid the effect of volume overload, almost always 
present immediately before the haemodialysis treatment in the most commonly used thrice 
weekly in-centre schedule. PAPs was measured according to the modified Bernoulli equation: 
PAP = 4 x (peak tricuspid regurgitant jet velocity)2 + 10 mmHg (estimated right atrial pressure, 
RAP). Patients with cardiac, pulmonary or systemic diseases known to associate with PH were a 
priori excluded in these earlier studies. A somewhat different approach was used in a 
prospective study from Texas, USA (Ramasubbu et al, 2010), including 90 HD patients (64% 
afro-american, 18% Hispanic and 18% Caucasian), dialyzed trough arterio-venous graft (44%), 
AVF (40%) or catheters (16%). Patients underwent comprehensive echocardiographic 
examination before the haemodialysis session, because it was felt that the pre-dialysis status of 
the patients more closely reflects the chronic volume status than the immediate post dialysis 
“dry weight” state. Furthermore, PH was defined as a peak tricuspid regurgitant (TR) jet 
velocity ≥ 2,5 m/sec, and as “more severe PH” when TR jet velocity was ≥ 3 m/sec. Forty-two 
patients (42%) met the definition of PH, 18 of whom (20%) of more severe grade. Quite 
surprisingly, patients with PH did have a significantly lower BMI. As expected, on the other 
hand, patients with PH were found to have larger right atrial (RA) and right ventricular (RV) 
sizes, higher RAP, and a trend towards decreased RV function and more left ventricular (LV) 
hypertrophy. Mean LVEF tended to be lower with increasing PAPs, but was still overall 
preserved. There was a trend to larger left atrial (LA) size with increasing PAPs, consistent with 
significantly higher estimates of left sided filling pressures. After 12 months, 14 patients (15,6%) 
had died. Mortality was significantly higher in patients who had PH (26%), particularly in those 
with a TR jet velocity ≥ 3 m/sec. Patients who died had been longer on HD, and they had larger 
RA and RV sizes, worse RV function, more severe TR, significantly higher RAP, PAPs and 
pulmonary capillary wedge pressure (PCWP). This study provides evidence that development 
of PH in HD patients may well reflect the consequence of chronic volume overload and 
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chronically elevated left heart filling pressures, suggesting that elevated PCWP may play a 
major role in PAP increase. Of note, in this study population 77% of the patients exhibited 
abnormal LV diastolic function, possibly the result of LVH and myocardial stiffness.  
Three studies attempt to explore specifically the role of the AVF in determining PH in CKD 
patients. The first published study (Acarturk et al, 2008) used mean PAP calculated from the 
right ventricular outflow tract acceleration time according to the Mahan’s equation (mPAP 
in mmHg =79 – 0.45 x acceleration time in ms); AVF blood flow rate was estimated by 
Doppler sonography. Thirty-two patients were included, 24 with a radial and 8 with a 
brachial AVF created 32±34 months before evaluation. PH (defined as mPAP > 25 mmHg,) 
was detected in 14 patients (43%). Results confirmed the already reported relationship 
between PAP and cardiac index (CO normalized to body surface area) and disclosed a 
higher cardiac index in patients with PH. No direct relationship between AVF blood flow 
rate and mPAP could be demonstrated, however. The second study (Beigi et al, 2009), did 
find a statistically significant positive correlation between AVF flow and PAP in 34 patients 
studied before AVF creation and at least 6 months apart. The mean AVF flow was 1322 
ml/min in patients without PH and 2750 ml/min in patients with PH, the latter being 
clearly higher than currently regarded as necessary and safe, even more when considering 
that the authors reported a negative correlation between PAP and ejection fraction (EF) 
before as well as after the creation of AVF. The third study (Ünal et al, 2010) included 20 
patients evaluated before AVF creation and 23±2 months later, failed to find an effect of 
AVF creation on PAP, which indeed tend to decrease after AVF creation and initiation of 
RRT, and a correlation between PAP and AVF blood flow rate (truly not given). A further 
study with an original design has been recently published (Kiykim et al, 2010). Seventy-four 
HD patients dialyzed through permanent tunnelled jugular central venous catheter (CVC) 
were studied echocardiographically immediately before and at the end of a HD session with 
two different dialysis membrane – cellulose acetate and high-flux polysulfone – in a cross-
over design. Pre-HD PH prevalence was remarkably high (68,8%, moderate in 40,5%). A 
significant PAP reduction and a significant correlation with UF volume was observed only 
when patients where dialyzed with the more biocompatible polysulfone membrane, 
suggesting a role for biocompatibility on short-term PAPs.  
2.2 Pulmonary hypertension in patients on Peritoneal Dialysis 
Apart from the data on 5 patients on peritoneal dialysis (PD) included in the control group 
of the first study from Yigla and co-workers (Yigla et al, 2003), none of whom found to have 
PH, the first study of PH in PD patients was published in 2007 (Kumbar et al, 2007). In this 
retrospective study including 36 patients undergoing echocardiographic evaluation on 
clinical indication, a PH prevalence of 42% was found. Due to the selection bias, however, 
patients with congestive heart failure and/or coronary artery disease were probably 
overrepresented in the study; indeed, patients with PH exhibited more dilated left 
ventricular chamber and their mean EF (46±19 %) would have represented a reason for 
exclusion in most of the previously published studies. An unexplained higher PH 
prevalence in patients on continuous cycling PD (CCPD) as compared to continuous 
ambulatory PD (CAPD) was noted. Duration of PD was not reported, but overall residual 
renal function was marginal. Two years later, to date the largest study on PH in PD patients 
was published (Ünal et al, 2009). One hundred and thirty five, quite young (47±13 years old) 
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patients on CAPD (64 females) were studied and, notably, this is the first study which 
included a bioelectrical impedance analysis to estimate the ratio of extracellular water 
(ECW) to total body water (TBW) and thus stratified patients according to volume status. 
PH was found in 17 patients (12,6%), who showed also significantly higher ECW/TBW ratio 
and lower serum albumin, triglyceride and ejection fraction. No differences were found 
between patients with PH and patients without in terms of age, gender, smoking, diabetes 
or hypertension, use of erythropoietin (EPO), duration of dialysis, systolic and diastolic 
blood pressure, body mass index (BMI), white blood cell count, haemoglobin (Hb), serum 
creatinine, solute clearances, residual glomerular filtration rate (GFR), alkaline phosphatise, 
intact parathyroid hormone (iPTH), hs-CRP, LDL and total cholesterol, calcium-phosphate 
product, amount of ultrafiltration (UF), left ventricular mass (LVM), and hypertrophy 
(LVH) and plasma level of asymmetric dimethylarginine (ADMA). Echocardiographically 
estimated PAPs correlated with ECW/TBW ratio, LVM and LVMI, and, inversely, with 
serum albumin, trygliceride, Hb and EF. In multivariate analysis, serum albumin, 
ECW/TBW and LVMI were found to be independent risk factors for PH. According to 
bioelectrical impedance analysis no patient was hypovolemic, 51 (37,8%) of the 135 patients 
were hypervolemic and 84 (62,2%) were normovolemic. Hypervolemic patients had lower 
Hb levels, higher mean systolic PAP and a significantly higher prevalence of PH (27,5% vs 
3,6%, p=0.001). These findings are highly suggestive of a major role for fluid overload in 
determining PH in PD patients and the same should hold true for all CKD disease patients, 
regardless of dialysis modality, and even for those on conservative pre-dialysis treatment. 
An Italian study (Fabbian et al, 2011) including 29 patients on HD and 27 patients on PD 
found PH in 22 patients (39%), and confirmed a higher prevalence in patient on HD (58,6% 
versus 18,5%, p=0.002). Patients with PH had been longer on RRT, had higher inter-dialytic 
weight gain, lower diastolic pressure and ejection fraction than those without. PH positively 
correlated with diastolic left ventricular volume (r = 0.32, p=0.013) and negatively with EF  
(r = -0.54, p< 0.0001).  
2.3 Pulmonary hypertension and mortality 
The impact of PH on mortality of patients undergoing chronic HD was investigated by Yigla 
and co-workers (Yigla et al, 2009) in a retrospective study including 127 HD patients 
representative of the national cohort of patients on HD in Israel. Including also patients with 
already known cardiac disease, but using a higher threshold cut-off value ( ≥ 45 mmHg) for 
PH definition, the prevalence of PH in the whole cohort was found to be 29,1%, and it was 
present before dialysis initiation in 13,4%, while developed after HD initiation in 15,7%. In 
latter group, the time interval to the first echocardiographic study showing PH was less than 
1 year in 75% of the cases. No differences in baseline cardiac status could be demonstrated 
between patients without PH at any time and patients developing PH after the initiation of 
HD, that instead was significantly worse in patients with pre-existing PH. The overall 1-, 3-, 
and 5-year survival was 90.6, 66.9 and 52.8 %, respectively. Survival of patients with PH was 
significantly shorter than that of those without (78.6, 42.9 and 25.2 %, log-rank test 
p=0.0001), regardless PH was present before dialysis initiation or developed thereafter. The 
age of non survivors at HD initiation was meaningfully higher, however, yet a survival 
advantage was found in 20 patients without PH matched to the group with PH developed 
after dialysis initiation for age, gender, aetiology of kidney disease, location of vascular 
access and comorbidity.  
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Very interestingly, when PAPs was analyzed as a continuous variable, as it is, the authors 
were able to demonstrate an adjusted hazard ratio (HR) for mortality of 1.5 for each 10 
mmHg increase in PAPs (95% CI 1.2-1.9, p=0.0007). One pitfalls of this study is that patients 
who have had only one echocardiographic evaluation while on HD, showing no PH, were 
assumed and analyzed as having normal pre-HD PAPs, which is not necessarily true, as 
suggested by several papers reporting the possibility of actual modification of PAP in a 
substantial proportion of patients on RRT, which holds true in our experience.  
2.4 Pulmonary hypertension and renal transplantation 
The association between PH before transplantation and subsequent outcome was first 
addressed by a study from the Mayo Clinic College of Medicine, Rochester, MN, USA  
(Issa et al., 2008). In this retrospective analysis of 215 dialysis patients who have had an 
echocardiographic evaluation before renal transplantation, mean PAPs was found to be 
34±10 mmHg (range 21-71) in the whole cohort; 146 patients (68%) have PAPs < 35 mmHg 
(regarded as normal), 47 (22%) have moderately high PAPs (36-50 mm Hg) and 22 (10%) 
markedly elevated PAPs (> 50 mm Hg), suggestive of severe PH. Longer time on dialysis 
was the strongest correlate of higher PAPs pre-transplant (r= 0.252, p< 0.001), PH being 
detected in 25% of patients who had never been on RRT (pre-emptive Tx) or had received 
dialysis for less than 1 year, in 38% of those who had been on dialysis longer than 1 but less 
2 years, and in 58% of those who have been on dialysis for more than 2 years before 
transplantation. Patients with severe PH had a significantly higher risk of death (HR 3.75, 
1.17-11.97, p=0.025) early after Tx than patients with lower PAPs. Age was associated with 
both PAPs and mortality in this study. A significantly lower prevalence of PH (17%) was 
found in a cohort of 500 younger patients studied as a part of pre-transplant evaluation 
(Bozbas et al, 2009), and again PH was associated with longer duration of dialysis and HD 
as the RRT modality versus PD. Amongst echocardiographic data, LVEF was significantly 
lower and right and left atria diameters greater in patients with PH than in those without. 
The prevalence of LVH was higher in patients with PH, while the percentage of patient with 
diastolic dysfunction was not significantly different. Another recently published study 
(Zlotnick et al, 2010) investigated the possible relationship between pre-transplant 
echocardiograpically detected PH and early graft function. In 55 patients, 21 of whom (38%) 
with pH, the incidence of the composite outcome of delayed or slow graft function was 
found to be significantly higher in patients with pre-transplant PH (43 vs 6%, p=0.002), 
supporting the hypothesis that pre-transplant pulmonary hypertension could represent an 
independent predictor of early graft dysfunction.  
3. What we have done 
Sant’Andrea Hospital is a tertiary 450-bed University Hospital which began its activity in 
2003. At that time the burden of cardio-renal syndromes was increasingly recognized as an 
emerging epidemic and prompted a strict and motivated cooperation between Cardiologists 
and Nephrologists. In that context all patients with kidney disease underwent first a 
comprehensive cardiovascular evaluation by one experienced Cardiologist (L.D.B.), who 
acts as the referring physician responsible for individually tailored work up, treatment and 
follow up of patients with renal diseases. The first patients with CKD at our Institution were 
those referred to the nephrology outpatient clinic, the nephrology ward and the outpatients 
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dialysis facility. At the same time many patients with cardiac diseases were referred for a 
nephrological consultation due to evidence of renal dysfunction. This interplay helped to 
disclose a number of interesting and quite novel findings. Among these, the unexpected, 
and at that time largely underrecognized, high prevalence of elevated pulmonary artery 
pressure as detected by Doppler echocardiography was one of the main framework. At the 
beginning most CKD patients on maintenance RRT at our hospital had started dialysis 
elsewhere, with quite large differences of previous duration of RRT and co-morbidities 
burden. Pivotal to the evaluation of their cardiac status was conventional and tissue Doppler 
imaging (TDI) trans-thoracic echocardiography, performed by two sonographer-
experienced Cardiologists (F.P. & G.M.C.). In more detail, patients with stage 5 CKD on RRT 
underwent two-dimensional and M-mode study using an Acuson Sequoia® C 256 
ultrasound machine. Left ventricular diameters and wall thickness were measured 
according to the American Society of Echocardiography, left ventricular volumes were 
estimated using the z-derived method. LVEF was calculated using the Teicholz formula and 
further confirmed with Simpson’s technique in the 4-chamber view. Pulsed-wave Doppler 
of mitral inflow velocity was performed. The maximal tricuspid regurgitation velocity was 
measured by continuous wave Doppler echocardiography from the apical 4-chamber view. 
The highest peak velocity was recorded and the average peak velocity from 3 beats were 
calculated and used to calculate systolic pulmonary pressure according to the modified 
Bernoulli equation. Pulmonary hypertension was defined as a value of systolic pulmonary 
pressure > 35 mmHg at rest. Right ventricular diameters were measured in the long axis 
view. EF of the right ventricle was calculated by using the Simpson’s formula from the 
apical 4-chamber view. Early (E) and late (A) right ventricular inflow velocity were 
measured with pulse-wave Doppler by placing the sample volume in between the tips of the 
tricuspid valve in the apical 4-chamber window. TDI spectral signal was acquired from the 
apical 4-chamber view, with the sample volume placed along the lateral and septal tricuspid 
annulus. The systolic myocardial velocity (Sm), protodiastolic myocardial velocity (Em), and 
late peak diastolic myocardial velocity (Am) were measured. The E/Em ratio, an index of 
ventricular filling pressure, was calculated. Ejection time, isovolumic relaxation and 
contraction time were also measured. Regional TDI myocardial performance index (MPI) 
was calculated. Average regional TDI MPI of the right ventricle was calculated as follow: 
(MPI lateral + MPI septal ) /2. Right ventricular dysfunction (RVD) was defined by an average 
regional MPI value > 2 SD from the mean of the values derived from 100 healthy subjects 
(MPI>0.53). An early analysis included 68 patients on RRT, 54 (79%) on thrice weekly HD 
and 14 (21%) on PD, who did not differ in age, gender, height, weight, BMI, BSA, blood 
pressure, heart rate, serum calcium, phosphate, Ca x P product, uric acid, Hb, total 
cholesterol, triglyceride and total protein. Patients on PD had however significantly higher 
HDL cholesterol, lower serum albumin, shorter duration of RRT and more preserved 
residual renal function (RRF) than their HD counterpart. Patients on HD showed a 
significantly higher left and right ventricular wall thickness, higher PAPs (35±8 versus 28±9 
mmHg) and higher left ventricular mass index (p<0.01). A significant correlation was found 
between PAPs and some measures of diastolic and systolic function of the right ventricle, 
such as isovolumic relaxation time (IVRT) (r=0.414, p=0.003) and Sm (r= -0.454, p=0.001). 
Both these measures were significantly more compromised in the HD cohort. As long as 
CKD patients new to dialysis entered our RRT program, we were able to extend our 
observation in a larger study (Paneni et al, 2010), including 94 patients on HD, 62 dialyzed 
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trough a radial AVF and 32 trough a brachial AVF, and 26 on PD, most of whom on nightly 
automated PD (APD), compared with 100 healthy controls matched for age, gender and 
BMI. Patients on RRT did not differ with regards to the prevalence of hypertension and 
diabetes and type of medications used. Duration of dialysis tended to be longer in HD 
patients (45±3 months versus 37±3 in patients on PD) but this difference was no longer 
statistically significant. LV diameters and volumes were higher in dialysis patients than in 
controls. LVEF was significantly lower in HD patients than in PD patients and controls.  
No significant differences in the indices of systolic and diastolic function were found 
between HD patients with radial or brachial AVF. PAPs was significantly higher in HD 
patients than in PD patients and controls (38.9 ± 6.8, 29.7 ± 6.7 and 21.7 ± 6.8 mmHg, 
respectively, p< 0.001). Patients on HD presented larger right ventricular diameters than PD 
patients and controls; RVEF was significantly reduced in dialysis patients as compared to 
controls, but to a different extent in the HD and PD group. TDI indices of diastolic and 
systolic function were significantly lower in patients undergoing HD, and the impairment 
was more pronounced in those with a brachial AVF. Compared to PD patients, patients on 
HD showed a prolonged IVRT and higher E/EM ratio. Lateral and septal Sm velocities were 
reduced among HD patients, the greatest reduction being observed in patients with a 
brachial AVF. When right ventricular dysfunction was defined by a TDI MPI > 2 SD from 
the mean value derived from healthy controls, RVD was identified in 79 (65,8%) dialysis 
patients, the prevalence being significantly higher in HD as compared to PD patients (71.3 
versus 34.6%, p<0.001). RVD was significantly more prevalent in HD patients with a 
brachial versus radial AVF (90.6 versus 61.3%, p<0.001). TDI MPI of the right ventricle 
showed significant correlation with systolic PAP (r = 0.45, p<0.01), Sm velocity measured at 
both lateral and septal tricuspid annulus , Em velocity, Am velocity, right and left 
ventricular EF. Linear regression analysis adjusted for age, gender, heart rate, duration of 
dialysis, dialysis adequacy and PAPs, showed that HD treatment was independently 
associated with average TDI MPI of the right ventricle (ǃ = 0.34, p<0.001). Logistic 
regression analysis adjusted for the same confounding showed that patients on HD have an 
increased risk of RVD as compared to patient on PD (OR 6.3 95% CI 2-19.5, p<0.001). Our 
preliminary data deriving from longitudinal follow up examinations show that “aggressive” 
correction of over hydration, as addressed by bio-impedance spectroscopy, may result in 
significant reduction of PAPs and improvement of most indices of diastolic and systolic 
function of both ventricle, thus supporting a major role for chronic volume overload in 
determining overall cardiac compromise in our CKD patients.  
4. Summary 
4.1 Diagnosis 
The gold standard for the diagnosis of PH is right heart catheterization (RHC), usually 
performed as a pre-operative tool in cardiac surgery, for hemodynamic evaluation of the 
critically ill patient, or in the suspicion of severe PH. To the best of our knowledge, no study 
has been published to date systematically performing RHC in patients with kidney diseases. 
The whole literature on PH in CKD patients employed rather uniform echocardiographic 
criteria to detect PAPs. Reliance on echocardiography to diagnose PH has recently been 
mitigated, especially when pre-load is not controlled. The most recent consensus conference 
on PH, held in Dana Point in 2008, do not mention anymore echocardiographic parameters 
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for the diagnosis of PH, while citing for the first time dialysis-dependent CKD as a self-
standing entity among group 5, PH with unclear multifactorial mechanisms. It appears 
however unlikely that RHC will be largely used in this subset of patients, as long as the less 
invasive ultrasound study will refine to provide clinically adequate informations. To date, 
unfortunately, only the study from Ünal and co-workers on PD patients (Ünal et al, 2009) 
included an imperfect yet objective measure of the hydration status, which should be 
included in future studies on PH in CKD patients. 
4.2 The role of the AV haemodialysis access 
When PH was first detected in a high percentage of patients on maintenance HD, the 
possibility that AV access could play a major role in the development of PH was greatly 
emphasized. Subsequent studies, yet including relatively small numbers of patients, fail to 
demonstrate a major impact of AVF creation on PH in the short-medium term, with the 
possible exception of very high flow fistulas, in most cases brachial. It is our opinion that 
caution should be paid not to get excessively high, yet unnecessary, flow when creating 
arterio-venous access for RRT.  
4.3 PH and dialysis modality 
That the AV access cannot tell the whole story is clearly indicated by the absence of PH in 
about 50% of HD patients carrying an AVF and, on the other side, by the occurrence of PH 
in CKD patients without. PH prevalence and severity has been consistently reported to be 
lower in PD patients than in their HD counterpart (Domenici et al, 2010). One possible and 
little investigated explanation could well be the usually higher RRF of patients on PD, at 
least in the first years of RRT. A role for the differences in biocompatibility and 
intermittency schedules of different dialysis modalities seems likely, but has not been 
adequately explored. 
4.4 PH, inflammation and endothelial dysfunction 
A correlation between inflammation markers and PAPs has been suggested, but this link has 
not been investigated in a longitudinal perspective. The pathogenetic relevance of 
endothelial dysfunction in CKD appears likely, as suggested by the increasing evidence of a 
common pathway in sleep disordered breathing, PH, early renal Tx outcome and markers of 
endothelial dysfunction.  
4.5 PH and renal Tx 
Current limited evidence suggests that echocardiographically-estimated PAPs and RV 
function should be part of the pre-transplant evaluation, because of their prognostic 
relevance. Successful renal Tx is associated with normalization of PAPs and improvement of 
cardiac function in most, but not all, transplanted patients. 
5. Area for future research 
The prevalence and the clinical correlates of PH in CKD needs to be better defined in larger 
prospective studies, which should take into account volume status and RRF. Patients with 
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lower degree of renal impairment should be included, as well as patients with renal diseases 
but preserved glomerular filtration rate (GFR), such as nephrotics. PH has been recently 
detected in conjunction with sleep disordered breathing, a common co-morbidity in CKD 
patients that independently portends an unfavourable outcome. The prevalence and clinical 
relevance of PH in critically ill patients, its role as a risk factor for acute kidney injury (AKI) 
and its relevance to outcome warrants to be investigated. Studies focusing on the impact of 
different dialytic strategies and/or pharmacologic tools to efficaciously treat this condition 
in patients with CKD are urgently needed. 
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